West Pharmaceutical Services, Inc. (WST)
NYSE · Healthcare · Medical - Instruments & Supplies
Profile
West Pharmaceutical Services, Inc.
- Exchange
- NYSE
- Ticker
- WST
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- US
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Key facts
West Pharmaceutical Services, Inc.: key facts
- West Pharmaceutical Services, Inc. (NYSE: WST) is a Medical - Instruments & Supplies company in the Healthcare sector.
- In fiscal 2025, West Pharmaceutical Services, Inc. reported revenue of $3.1B and net income of $493.7M.
- Revenue grew 2.1% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $3.4B and net income was $638.9M.
MonkScore
West Pharmaceutical Services, Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 35 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth70–80
- Profitability80–90
- Quality90–100
- Market Conviction90–100
- Safety70–80
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
West Pharmaceutical Services, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.1B | $2.9B | $3.0B | $2.9B | $2.8B |
| Gross profit | $1.3B | $1.1B | $1.0B | $1.1B | $1.1B | $1.2B |
| Operating income | $780.2M | $617.4M | $594.6M | $710.9M | $763.5M | $758.7M |
| Net income | $638.9M | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Operating cash flow | $654.5M | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M |
| Capital expenditure | -$201.1M | -$285.9M | -$377.0M | -$362.0M | -$284.6M | -$253.4M |
| Free cash flow | $453.4M | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
| Total debt | $305.0M | $416.7M | $305.3M | $309.0M | $317.9M | $325.3M |
| Cash | $464.1M | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
Revenue growth a year
- 1-year
- 6.3%
- 3-year
- 2.1%
- 4-year
- 2.1%
Compound growth between fiscal years.
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.